157 related articles for article (PubMed ID: 36102985)
1. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W; Yanagisawa T; Hashimoto M; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Miki J; Oyama Y; Abe H; Kimura T
Cancer Immunol Immunother; 2023 Apr; 72(4):841-849. PubMed ID: 36102985
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
4. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH
Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
7. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
Gupta S; Andreev-Drakhlin A; Fajardo O; Fassò M; Garcia JA; Wee C; Schröder C
J Natl Cancer Inst; 2024 Apr; 116(4):547-554. PubMed ID: 38036464
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
9. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Ito K; Kita Y; Kobayashi T
Int J Urol; 2023 Sep; 30(9):696-703. PubMed ID: 36482843
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
16. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
Hunter L; Moser J; Sturge C; Barraza G; Colonna S
J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
[TBL] [Abstract][Full Text] [Related]
18. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee JL; Kanesvaran R; Lorenzo GD; Verolino P; Barata P; Bilen MA; Hussain SA; Curran C; Sonpavde G
Clin Genitourin Cancer; 2021 Oct; 19(5):425-433. PubMed ID: 34006497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
